Sovaprevir

Drug Profile

Sovaprevir

Alternative Names: ACH-0141625; ACH-1625

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors; Viral nonstructural protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Hepatitis C
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 22 Jul 2015 No recent reports on development identified - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in Belgium and Germany (PO)
  • 19 May 2015 Sovaprevir licensed to Janssen Pharmaceuticals worldwide
  • 08 May 2015 Achillion plans the SPARTA doublet regimen trial for Hepatitis C (Combination therapy, Treatment-naive) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top